Portugal Funds Briumvi for MS Only After First-Line Failures

The Ublituximab Portugal approval establishes public funding for adults with active relapsing multiple sclerosis who have not responded adequately to or cannot use first-line disease-modifying therapies including interferon beta, glatiramer acetate, dimethyl fumarate, fingolimod, and ozanimod. This decision limits reimbursement to later-line settings while recognizing added therapeutic value solely versus teriflunomide in treatment-naïve patients and confirming economic advantages through cost-minimization analysis.

Ublituximab Portugal Approval Framework

Portuguese authorities have anchored the ublituximab portugal approval to documented failure of lower-cost alternatives, thereby protecting healthcare budgets. The framework requires patients to demonstrate inadequate response or ineligibility before accessing ublituximab, reflecting a deliberate strategy to prioritize affordability without compromising clinical need.

Network Meta-Analysis Limitations

The evaluation drew on a network meta-analysis of only four randomized trials that linked ublituximab and ofatumumab exclusively through teriflunomide. This star-shaped geometry prevented inconsistency checks and reduced the reliability of indirect comparisons. Subgroup analyses separating treatment-naïve from previously treated patients further lowered statistical power and introduced potential bias by moving away from original randomization.

Ad

Clinical Evidence and Outcomes

In treatment-naïve adults, annualized relapse rates favored ublituximab over teriflunomide with a risk ratio of 0.41. No statistically significant differences appeared for confirmed disability progression at six months against either teriflunomide or ofatumumab. Previously treated patients showed comparable relapse and progression outcomes versus ofatumumab, yet direct evidence remained absent for the remaining comparators. Overall evidence quality received a low rating due to post-hoc subgroups, incomplete comparator coverage, and missing data on mortality or quality-of-life endpoints.

Economic and Strategic Consequences

Cost-minimization modeling, required once therapeutic equivalence was accepted, restricted comparisons to acquisition and administration costs. The ublituximab Portugal approval therefore channels prescribing toward later-line use, preserving resources for oral and injectable first-line options. Future health-technology assessments in multiple sclerosis may adopt explicit relapse-rate thresholds to determine added therapeutic value, given uncertainty around the current rating versus teriflunomide. Manufacturers seeking wider access will likely need head-to-head trials against additional high-efficacy agents to close the evidence gaps identified in the Portuguese review. This approach aligns with Infarmed’s ongoing emphasis on both clinical rigor and fiscal responsibility in multiple sclerosis care.